Pavmed Stock Price, News & Analysis

Lucid Diagnostics announced that the updated American College of Gastroenterology (ACG) clinical guideline supports esophageal precancer screening using its EsoGuard DNA Test. This represents a shift towards nonendoscopic screening methods, which are less invasive and can significantly increase screening rates for at-risk patients. The proposed Medicare Local Coverage Determination by Palmetto GBA's MolDX Program is also notable, allowing public comment before a meeting on May 10, 2022. These developments aim to reduce preventable esophageal cancer deaths in the U.S., especially among the GERD patient population.

Lucid Diagnostics Inc. (Nasdaq: LUCD) has announced that Dr. Lishan Aklog, CEO, will speak at the 21st Annual Needham Virtual Healthcare Conference from April 11-14. He is scheduled for a Fireside chat on April 12 from 1:30 - 2:10 pm ET. Lucid focuses on cancer prevention, particularly for patients with gastroesophageal disease (GERD) using its FDA Breakthrough Device-designated EsoGuard® test. The company is actively enrolling participants for clinical trials to support FDA approval, emphasizing its commitment to early detection of esophageal cancer.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) reported a business update and preliminary financial results for the year ended December 31, 2021. Key highlights include a significant increase in EsoGuard tests processed, reaching 303 in Q4 2021, a 50% sequential and nearly 200% annual growth. However, revenues for EsoGuard were only $0.3 million for Q4 and $0.5 million for the year. Operating expenses totaled approximately $54.3 million for 2021, resulting in a GAAP net loss of $50.6 million. The company had $77.3 million in cash at year-end and plans to raise up to $50 million through a new equity facility with Cantor Fitzgerald.

Lucid Diagnostics, a cancer prevention diagnostics company, reported its preliminary financial results for 2021, showcasing significant growth, particularly in EsoGuard testing volume, which rose nearly 200% year-over-year. The company processed 303 tests in Q4 2021, highlighting a 50% sequential increase. Operating expenses were about $27.3 million for the year, resulting in a net loss of $28.1 million. Lucid maintains a strong cash position of $53.7 million and has plans for further expansion in sales and testing programs. A conference call will provide additional insights at 4:30 PM EDT today.

Lucid Diagnostics Inc. (Nasdaq: LUCD) announces the enrollment of the first patient in a Department of Defense-funded study at the Cleveland VA. The study investigates the effectiveness of the EsoGuard Esophageal DNA Test for early detection of esophageal precancer in GERD patients. EsoGuard, shown to be 90% sensitive and specific, aims to improve screening efficiency and reduce unnecessary endoscopies. The study will enroll up to 100 patients and compare traditional endoscopy with EsoGuard testing, assessing its impact on screening rates and cost-effectiveness within the VA system.

Lucid Diagnostics has launched Lucid Test Centers in Seattle, Portland, and Boise, offering a non-invasive test to detect esophageal precancer for patients with chronic heartburn. These centers utilize the EsoCheck device to collect surface esophageal cells for the EsoGuard DNA test, aiming to prevent esophageal cancer through early detection. The rollout reflects an expansion of their EsoGuard commercialization strategy, building on the success of existing centers.

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announces successful implantation of its PortIO Intraosseous Infusion System in three patients in Barranquilla, Colombia. This marks the first human use of the device in a first-in-human clinical study approved for up to 40 patients. All implantations were successful, with no complications reported. The device aims to provide maintenance-free vascular access, addressing issues associated with existing devices that require regular maintenance and can lead to serious complications. The addressable market for PortIO is estimated at over $500 million.

PAVmed Inc. (PAVM, PAVMZ) has scheduled a business update conference call for March 29, 2022, at 4:30 PM EDT. CEO Lishan Aklog and CFO Dennis McGrath will discuss the company’s growth strategy and financial results for Q4 2021. PAVmed operates in medical devices and diagnostics, with major products like EsoGuard® and EsoCheck® for early esophageal cancer detection. The call will also provide insights on upcoming milestones and market strategies. For live access, listeners may dial designated numbers or visit the company’s investor relations page.

Lucid Diagnostics Inc. (Nasdaq: LUCD) will host a business update conference call on March 28, 2022, at 4:30 PM EDT, featuring CEO Lishan Aklog and CFO Dennis McGrath discussing growth strategies and financial results for Q4 2021. Lucid focuses on preventing esophageal cancer through its EsoGuard® test for patients with gastroesophageal disease (GERD). The company is awaiting regulatory approval for its diagnostic products, which are crucial for its future operations and potential market acceptance.